Biogen’s Spinraza and Novartis and AveXis’ Zolgensma provide “substantial health benefits” in the treatment of spinal muscular atrophy (SMA), according to a new assessment by the Institute for Clinical and Economic Review (ICER).
“Both of these treatments appear to dramatically improve the lives of children with SMA, as well as the families who take care of them,” ICER CMO David Rind said in a statement.
According to a press release, the new report will be discussed by the New England Comparative Effectiveness Public Advisory Council’s March 7 meeting in Boston.
ICER recommended a $72,000-$130,000 price tag for the first year of treatment with Spinraza, and $36,000-$65,000 for each year after. The organization recommended a price of $310,000-$900,000 per treatment in the infantile-onset (Type I) population.
To read the full press release, click here.